Sort   by:  
 Page size 
TranscriptomicsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers [methylation]
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidin...
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57342 | biostudies-arrayexpress
TranscriptomicsImmune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57343 | biostudies-arrayexpress
TranscriptomicsEffect of AZA on gene expression of multiple breast, colon, and ovarian cell lines [expression]
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidin...
ORGANISM(S): Homo sapiens 
2014-05-08 | E-GEOD-57341 | biostudies-arrayexpress
GenomicsRNA seq analysis of MEK inhibitor in combination with 5-azacitidine treated Shp2E76K/+ driven JMML mice
RNA seq analysis of MEK inhibitor in combination with 5-azacitidine treated Shp2E76K/+ driven JMML mice
PRJNA869713 | ENA
GenomicsSUMOylation inhibitor TAK-981 (Subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia
SUMOylation inhibitor TAK-981 (Subasumstat) synergizes with 5-azacitidine in preclinical models of acute myeloid leukemia
PRJNA875058 | ENA
UnknownInhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine.
Not available
S-EPMC8021029 | biostudies-literature
GenomicsEnhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [OCI_ly7_RNAseq_Day5]
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [OCI_ly7_RNAseq_Day5]
PRJNA1365727 | ENA
GenomicsEnhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [RRBS]
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [RRBS]
PRJNA1294225 | ENA
GenomicsEnhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [MD901_RNAseq_Day5]
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma [MD901_RNAseq_Day5]
PRJNA1291740 | ENA
GenomicsRestoration of genome-wide 5-hydroxymethylation by azacitidine and ascorbate in TET2-deficient human pre-leukemic HSPCs
Restoration of genome-wide 5-hydroxymethylation by azacitidine and ascorbate in TET2-deficient human pre-leukemic HSPCs
PRJNA817283 | ENA
Sort   by:  
 Page size